About this Research Topic
Lung cancer is one of the leading causes of cancer-related mortality and morbidity worldwide. It has led to over 1 million deaths annually and is responsible for one-third of all cancer-related deaths globally. Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases which includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Lung cancer has poor overall survival outcome and prognosis due to the high rates of drug resistance, recurrence and metastasis. Therefore, there is ongoing research and development with treatment and therapies available for lung cancer patients. There is a specific interest in combinatorial immunotherapy strategies which are currently being explored and studied due to the success of immune checkpoint blockade in NSCLC patients. However, the response rate to these therapies remains unsatisfactory and further research is required.
Immunotherapies aim to restore mediated anti-tumor immunity in T cells and also suppress the pro-tumor activities in the tumor microenvironment (TME). The TME consists of tumor, endothelial, fibroblasts and immune cells known as the central regulator of malignant tumor progression. Studies have demonstrated the presence of tumor-infiltrating lymphocytes such as CD8+ and CD4+ cells, which were found to influence cancer progression. Therefore, understanding the correlation between tumor immunity and the influence it has on the TME is essential to enhance the potential efficacy of immunotherapy. Studies have also demonstrated analysing gene expression or copy numbers in lung cancer samples can further our understanding of immune cell infiltration into the TME. There have also been studies on non-coding influences from gene expression that influence TME.
This Research Topic welcomes Original Research, Reviews, Systematic Reviews, Mini Reviews and Perspectives with a focus on the role of the tumor microenvironment on lung cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Immunotherapies aim to restore mediated anti-tumor immunity in T cells and also suppress the pro-tumor activities in the tumor microenvironment (TME). The TME consists of tumor, endothelial, fibroblasts and immune cells known as the central regulator of malignant tumor progression. Studies have demonstrated the presence of tumor-infiltrating lymphocytes such as CD8+ and CD4+ cells, which were found to influence cancer progression. Therefore, understanding the correlation between tumor immunity and the influence it has on the TME is essential to enhance the potential efficacy of immunotherapy. Studies have also demonstrated analysing gene expression or copy numbers in lung cancer samples can further our understanding of immune cell infiltration into the TME. There have also been studies on non-coding influences from gene expression that influence TME.
This Research Topic welcomes Original Research, Reviews, Systematic Reviews, Mini Reviews and Perspectives with a focus on the role of the tumor microenvironment on lung cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: lung cancer, tumor microenvironment, oncology, non-small cell lung cancer, immune related genes, biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
